Manifestaciones hepatobiliares en la enfermedad inflamatoria intestinal

Herruzo, J. A. Solís; Solís‐Muñoz, Pablo

doi:10.4321/s1130-01082007000900008

Cited by 5 publications

(8 citation statements)

References 231 publications

(226 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yang et al [ 5 ] found that 35.97% of 606 IBD patients had cholelithiasis, and 68.81% of them had NAFLD. Solis et al [ 8 ] also found hepatobiliary complications in IBD patients, higher risk in which was showed in Parente’s study [ 6 ]. Zhang et al [ 31 ] found necrosis of hepatic cells in liver tissues of mice CD model, and also found lymphocytic infiltration around the central vein and central intralobular in this model without bile duct damage.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice

et al. 2018

View full text Add to dashboard Cite

BackgroundA variety of extra-intestinal manifestations (EIMs), including hepatobiliary complications, are associated with inflammatory bowel disease (IBD). Mesenchymal stem cells (MSCs) have been shown to play a potential role in the therapy of IBD. This study was designed to investigate the effect and mechanism of MSCs on chronic colitis-associated hepatobiliary complications using mouse chronic colitis models induced by dextran sulfate sodium (DSS).MethodsDSS-induced mouse chronic colitis models were established and treated with MSCs. Severity of colitis was evaluated by disease activity index (DAI), body weight (BW), colon length and histopathology. Serum lipopolysaccharide (LPS) levels were detected by limulus amebocyte lysate test (LAL-test). Histology and liver function of the mice were checked correspondingly. Serum LPS levels and bacterial translocation of mesenteric lymph nodes (MLN) were detected. Pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-1β (IL-1β), interleukin-17A (IL-17A), Toll receptor 4 (TLR4), TNF receptor-associated factor 6 (TRAF6) and nuclear factor kappa B (NF-κB) were detected by immunohistochemical staining, western blot analysis and real-time PCR, respectively.ResultsThe DSS-induced chronic colitis model was characterized by reduced BW, high DAI, worsened histologic inflammation, and high levels of LPS and E. coli. Liver histopathological lesions, impaired liver function, enhanced proteins and mRNA levels of TNF-α, IFN-γ, IL-1β, IL-17A, TLR4, TRAF6 and NF-κB were observed after DSS administration. MSCs transplantation markedly ameliorated the pathology of colon and liver by reduction of LPS levels and proteins and mRNA expressions of TNF-α, IFN-γ, IL-1β, IL-17A, TLR4, TRAF6 and NF-κB.ConclusionsMSCs can improve chronic colitis-associated hepatobiliary complications, probably by inhibition of enterogenous endotoxemia and hepatic inflammation through LPS/TLR4 pathway. MSCs may represent a novel therapeutic approach for chronic colitis-associated hepatobiliary complications.

show abstract

Section: Discussionmentioning

confidence: 85%

“…As all know, inflammatory cytokines, causing damages to colon and intestinal mucosal barrier, are increased in IBD. It is reported that intestinal endotoxemia (IETM) may be the important pathogenesis mechanism of NAFLD [ 8 ]. Animal studies also proved the relevance between bacterial translocation and liver diseases.…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Thus, triglycerides are retained within the hepatocytes resulting in fatty liver. Increased import of free fatty acids into the liver as a result of abdominal lipolysis, which develops during the weight-loss stages, may add to this process[ 32 ]. This finding is in agreement with our study, in which 10 patients had echogenic liver by ultrasound; 3 of them were receiving steroids, 3 patients had malnutrition with poor growth according to the Egyptian growth curves[ 25 ], and 4 patients had both risk factors.…”

Section: Discussionmentioning

confidence: 99%

Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country

El-Shabrawi¹,

Tarek²,

Abou-Zekri³

et al. 2020

WJGPT

View full text Add to dashboard Cite

BACKGROUND There has been a worldwide increase in the reported incidence of inflammatory bowel disease (IBD) in children over the past 2-3 decades. The hepatobiliary (HB) manifestations of IBD have been well-studied in children in industrialized and developed countries but are infrequently reported in low- and middle-income countries (LMIC) such as Egypt. AIM To determine the prevalence of the HB manifestations in a cohort of Egyptian children with IBD. METHODS This cross-sectional observational study was carried out over a period of 6 mo (between June 2013 to December 2013) at the Paediatric Hepatology and Gastroenterology Units of Cairo University Children's Hospital, which is the largest paediatric tertiary care centre in the country. RESULTS The study included 48 patients with confirmed IBD based upon clinical, laboratory, endoscopic and histopathological features, 29 (60.4%) were male. Twenty-four patients (50%) had ulcerative colitis (UC), 11 (22.9%) had Crohn's disease (CD) and 13 (27.1%) had unclassified-IBD (IBD-U), which was formerly known as indeterminate colitis. The mean age of the patients at the time of presentation was 8.14 (± SD 4.02) years and the mean age at the time of study enrolment was 10.16 (± SD 4.19) years. All patients were screened for HB manifestations by physical examination, liver function tests, imaging and liver biopsy when indicated. HB disorders were confirmed in 13 patients (27.1%). Transaminases were elevated in 3 patients (6.3%). Two patients (4.2%) had elevated biliary enzymes (one was diagnosed as primary sclerosing cholangitis (PSC) and the other was diagnosed with PSC/autoimmune hepatitis overlap syndrome and the third patient had hepatitis C virus infection. Ten patients (20.8%) had bright echogenic liver on ultrasound suggesting fatty infiltration as a sequel of malnutrition or medication toxicity. CONCLUSION The commonest HB disorders in Egyptian children with IBD were abnormal liver function tests, fatty infiltration and PSC. These HB manifestations in paediatric patients in LMIC may be relatively more common than in industrialized countries. Therefore, IBD patients in LMIC should be meticulously screened for liver disease to allow prompt diagnosis and management.

show abstract

“…In addition, a relationship of incidence of hepatic damage in patients with inflammatory diseases such as ulcerative colitis (17) has been found recently, which may be due to the passage of bacteria or endotoxins from the intestine to liver, that produces an inflammation of the liver and hepatobiliary damage, this condition is specifically termed cholangitis (18,19). In patients with NAFLD the damage derived from UC can be a factor of susceptibility for progress to non-alcoholic steatohepatitis (NASH).…”

Section: Denitrase Activity Of Debaryomyces Hansenii Reduces the Oxidmentioning

confidence: 99%

Denitrase activity of Debaryomyces�hansenii reduces the oxidized compound 3‑nitrotyrosine in mice liver with colitis

et al. 2019

View full text Add to dashboard Cite

The oxidation of tyrosine to 3-nitrotyrosine is irreversible, and due to this characteristic, 3-nitrotyrosine is used as a marker for oxidative stress in a range of diverse chronic and degenerative diseases. It has been established that the yeast Debaryomyces hansenii (D. hansenii) can assimilate free 3-nitrotyrosine as unique source of nitrogen, and during saline stress, has a high denitrase activity to detoxify this compound in a reaction that involves the liberation of nitrogen dioxide from 3-nitrotyrosine. However, until now it has not been determined whether D. hansenii can detoxify protein-bound 3-nitrotyrosine such as nitrated proteins present in different chronic illnesses. TThe aim of the present study was to evaluate the denitrase activity of D. hansenii to reduce 3-nitrotyrosine from liver proteins of mice with colitis. Firstly, the levels of reactive oxygen species of liver tissue of colitic and control mice were measured by the reaction with the 2'7'-dichlorofluorescein diacetate. Denitrase activity of D. hansenii was evaluated by incubating cell extracts of the yeast with protein extracts from livers of mice with colitis. Following incubation, 3-nitrotyrosine was measured, and to corroborate that denitrase reaction had occurred, the production of nitrites was measured. In samples of liver tissue from mice with colitis, the maximum levels of reactive oxygen species were up to two times higher compared with the control livers. Following the incubation of colitic liver samples with cell extracts of D. hansenii, it was observed that 3-nitrotyrosine decreased to the basal concentration of control liver samples, and that the concentration of nitrites was increased. These results indicate that denitrase of D. hansenii extracts can effectively detoxify 3-nitrotyrosine bound to proteins and that the extracts could be used to decrease protein oxidation damage in chronic degenerative diseases.

show abstract

Manifestaciones hepatobiliares en la enfermedad inflamatoria intestinal

Cited by 5 publications

References 231 publications

Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice

Mesenchymal stem cell transplantation improves chronic colitis-associated complications through inhibiting the activity of toll-like receptor-4 in mice

Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country

Denitrase activity of Debaryomyces�hansenii reduces the oxidized compound 3‑nitrotyrosine in mice liver with colitis

Contact Info

Product

Resources

About